The UK's National Institute of Health Research (NIHR) has recently announced its intention to withdraw the infrastructure funding that it provides to all UK Cochrane Review Groups, including Cochrane Epilepsy. Our funding will cease on 31st March 2023, after which there will be no editorial base to support Cochrane Reviews to publication.
We are busy investigating alternative funding arrangements and opportunities, although it is early days and we cannot be sure of the plans for the future Cochrane Epilepsy at this time.
For authors of protocols, reviews and updates already in development
We are committed to continuing to support all titles already agreed and in progress, through to publication. As we are not certain of our place as an editorial unit beyond 31 March 2023, we would ideally like to see all active titles published in The Cochrane Library by that date. However, we understand that this may not be feasible, and we would like to reassure our author teams that there will always be a route to publication for high quality Cochrane Reviews. We are here to provide guidance to any authors whose reviews need to be supported into April 2023 and beyond.
For authors of reviews that are due to be (re)assessed for updating
Unfortunately, we are no longer able to routinely commit to assessing reviews for updating, as we would do under normal circumstances. However, we are open to discussion with author teams if there is a strong reason for updating, for example there is new evidence which may change the conclusions in a high priority review, and there is secure funding to support the update.
For authors planning on proposing a new title
Unfortunately we are currently closed to new title proposals. If you would like to propose a high priority, funded review, we would be open to discussion, but we do not have the capacity or resources to commit to starting new titles over the next 18 months.
We are committed to finding a new funding stream to continue our important work and to contribute to better health in our communities beyond March 2023. We are engaging with our Cochrane colleagues regarding the future restructuring of evidence synthesis (see here for more information).